• Publications
  • Influence
Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity
The results suggest that intravenous administration of this vaccine will lead to the prevention of infection with Plasmodium falciparum malaria and suboptimally immunogenic and protective. Expand
Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.
This first demonstration in healthy naïve humans of the induction of CD8+ C TLs by DNA vaccines, including CTLs that were restricted by multiple HLA alleles in the same individual, provides a foundation for further human testing of this potentially revolutionary vaccine technology. Expand
Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits.
Tissue distribution studies in mice and safety studies in rabbits were conducted with VCL-2510, a plasmid DNA encoding the gene for the malaria circumsporozoite protein from Plasmodium falciparum, and no evidence of autoimmune-mediated pathology, anti-nuclear antibodies (ANA), or antibodies to dsDNA were observed in the mouse or rabbit studies. Expand
Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.
Despite induction of excellent CTL responses, intramuscular DNA vaccination via needle injection failed to induce detectable antigen-specific antibodies in any of the volunteers. Expand
Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection.
A preclinical safety study was conducted in mice to determine the structural nature of plasmid DNA sequences persisting in total muscle DNA at both 30 and 60 days following a single intramuscular injection of a plasmids expressing the Plasmodium falciparum circumsporozoite protein. Expand
Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF
One potential benefit of DNA vaccines is the capacity to elicit antibody and T-cell responses against multiple antigens at the same time by mixing plasmids expressing different proteins. A possibleExpand
Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice.
To develop a nucleic acid vaccine against dengue type-2 virus, the PreM and 92% of the envelope (E) genes were cloned into different eukaryotic plasmid expression vectors (pkCMVint Polyli andExpand
Malaria DNA vaccines in Aotus monkeys.
It is demonstrated in Aotus monkeys that an intradermal route of immunization with a PyCSP plasmid DNA vaccine generates antibody responses equivalent to a multiple antigen peptide/adjuvant based vaccine, and that these data support the use of the intrader mal route for initial studies of the efficacy of DNA vaccines. Expand
Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine
In GLP safety studies in mice and rabbits, repeated intramuscular/intradermal administration of the MuStDO 5 vaccine was found to be safe and well tolerated without any evidence of autoimmune pathology. Expand
DNA vaccines against malaria: immunogenicity and protection in a rodent model.
Progress achieved in development of DNA vaccines that can protect mice from infection by the rodent malaria parasite Plasmodium yoelii is summarized, initial studies of immunogenicity of a malaria DNA vaccine in a primate model are described, and strategies being employed to design the next generation of malaria DNA vaccines are outlined. Expand